References
- Cervantes F. Modern management of myelofibrosis. Br J Haematol 2005; 128: 583–592
- Reilly J T. Idiopathic myelofibrosis: pathogenesis to treatment. Hematol Oncol 2006; 24: 56–63
- Jacobson R J, Salo A, Fialkow P J. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978; 51: 189–194
- Dupriez B, Morel P, Demory J L, Lai J L, Simon M, Plantier I, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013–1018
- Cervantes F, Pereira A, Esteve J, Rafel M, Cobo F, Rozman C, Montserrat E. Identification of ‘short-lived’ and ‘long-lived’ patients at presentation of idiopathic myelofibrosis. Br J Haematol 1997; 97: 635–640
- Cervantes F, Barosi G, Demory J L, Reilly J, Guarnone R, Dupriez B, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998; 102: 684–690
- Tefferi A, Huang J, Schwager S, Li C Y, Wu W, Pardanani A, Mesa R A. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer 2007; 109: 2083–2088
- Rupoli S, Da Lio L, Sisti S, Campanati G, Salvi A, Brianzoni M F, D'Amico S, Cinciripini A, Leoni P. Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival. Ann Hematol 1994; 68: 205–212
- Okamura T, Kinukawa N, Niho Y, Mizoguchi H. Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients. Int J Hematol 2001; 73: 194–198
- Bench A J, Pahl H L. Chromosomal abnormalities and molecular markers in myeloproliferative disorders. Semin Hematol 2005; 42: 196–205